Non-invasive imaging systems and methods of use

Abstract

Some embodiments of the present disclosure are directed to ultraweak photon emission imaging systems and methods. In some embodiments, a method comprises acquiring an ultraweak photon emission image of a target area of a patient for detection of a pathological condition; wherein the target area comprises an area of interest and a portion surrounding the area of interest, wherein acquiring the image comprises: enhancing formation of reactive oxygen species and/or reactive nitrogen species in the target area, wherein enhancing formation of the reactive oxygen species and/or the reactive nitrogen species comprises applying low level light illumination to the target area from 1 second to 60 minutes so as to achieve a total power output from 1 mW to 10,000 W using an average power density from 0.1 W/cm2 to 1 W/cm2; and imaging the target area, wherein imaging the target area comprises a total exposure time from 1 second to 60 minutes.

What is claimed: 
     
         1 . A method, comprising:
 acquiring an ultraweak photon emission image of a target area of a patient for detection of a pathological condition;
 wherein the target area comprises an area of interest and a portion surrounding the area of interest, 
 wherein acquiring the image comprises:
 enhancing formation of reactive oxygen species and/or reactive nitrogen species in the target area,
 wherein enhancing formation of the reactive oxygen species and/or the reactive nitrogen species comprises applying low level light illumination to the target area from 1 second to 60 minutes so as to achieve a total power output from 1 mW to 10,000 W using an average power density from 0.1 W/cm 2  to 1 W/cm 2 ; and 
 
 imaging the target area,
 wherein imaging the target area comprises a total exposure time from 1 second to 60 minutes. 
 
 
   
     
     
         2 . The method of  claim 1 , wherein applying low level light illumination comprises using a plurality of illumination sources. 
     
     
         3 . The method of  claim 1 , wherein applying low level light illumination comprises applying a continuation light wave. 
     
     
         4 . The method of  claim 1 , wherein applying low level light illumination comprises applying a pulsed light wave. 
     
     
         5 . The method of  claim 1 , wherein the low level light illumination comprises wavelengths from 600 nm to 1100 nm. 
     
     
         6 . The method of  claim 1 , further comprising applying red light illumination to the target area from 1 second to 5 minutes. 
     
     
         7 . The method of  claim 1 , further comprising applying white light illumination to the target area from 1 second to 1 minute. 
     
     
         8 . The method of  claim 1 , wherein enhancing formation of the reactive oxygen species and/or the reactive nitrogen species in the target area comprises applying cryotherapy, thermal therapy, fluidotherapy, hydrotherapy, ultrasound, heat lamp, diathermy, or any combination thereof to the target area. 
     
     
         9 . A method of treating cardiovascular diseases, comprising:
 obtaining a drug for treating cardiovascular diseases based on:
 an acquired ultraweak photon emission image of a target area of a patient;
 wherein the target area comprises an area of interest and a portion surrounding the area of interest, 
 wherein acquired the ultraweak photon emission image comprises:
 enhancing formation of reactive oxygen species and/or reactive nitrogen species in the target area, 
  wherein enhancing formation of the reactive oxygen species and/or the reactive nitrogen species comprises applying low level light illumination to the target area from 1 second to 60 minutes, and 
 imaging the target area, 
  wherein imaging the target area comprises a total exposure time from 1 second to 60 minutes; 
 
 
 a measured amount of ultraweak photon emission in area of interest in the acquired image of the target area; and 
 a correlation of the measured amount of ultraweak photon emission in the area of interest of the target area to the cardiovascular diseases reducing drug,
 wherein the cardiovascular diseases reducing drug is selected from group consisting of anticoagulants, aldosterone inhibitors, antiplatelet agents and dual antiplatelet therapy, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, angiotensin receptor-neprilysin inhibitors, beta blockers, calcium channel blockers, cholesterol-lowering medications, digoxin, digitalis preparations, diuretics, inotropic therapy, proprotein convertase subtilisin kexin type  9  (PCSK9) inhibitors, vasodilators, anti-inflammatory drugs, or any combination thereof; and 
 
   administering the cardiovascular disease reducing drug to treat the cardiovascular diseases.   
     
     
         10 . The method of  claim 9 , wherein applying low level light illumination to the target area comprises achieving a total power output from 1 mW to 10,000 W using an average power density from 0.1 W/cm 2  to 1 W/cm 2 . 
     
     
         11 . A method of treating neurological disorders, comprising:
 obtaining a neurological disorder reducing drug for treating neurological disorder based on:
 an acquired ultraweak photon emission image of a target area of a patient;
 wherein the target area comprises an area of interest and a portion surrounding the area of interest, 
 wherein acquired the ultraweak photon emission image comprises:
 enhancing formation of reactive oxygen species and/or reactive nitrogen species in the target area, 
  wherein enhancing formation of the reactive oxygen species and/or the reactive nitrogen species comprises applying low level light illumination to the target area from 1 second to 60 minutes, and 
 imaging the target area, 
  wherein imaging the target area comprises a total exposure time from 1 second to 60 minutes; 
 
 
 a measured amount of ultraweak photon emission in area of interest in the acquired image of the target area; and 
 a correlation of the measured amount of ultraweak photon emission in the area of interest of the target area to the neurological disorder reducing drug,
 wherein the neurological disorder reducing drug is selected from group consisting of analgesics, anesthetics, anorexiants, anticonvulsants, antipyretics, antiemetic/antivertigo agents, antiparkinson agents, anxiolytics, sedatives, and hypnotics, cholinergic agonists, cholinesterase inhibitors, CNS stimulants, drugs used in alcohol dependence, general anesthetics, melatonin, miscellaneous central nervous system agents, muscle relaxants, neuromuscular blockers, neuroprotective agents, parasympathomimetics, psychoactive drugs, sympathomimetics, nervous system drug stubs, VMAT 2  inhibitors, or any combination thereof; and 
 
   administering the neurological disorder reducing drug to treat the neurological disorder.   
     
     
         12 . The method of  claim 11 , wherein applying low level light illumination to the target area comprises achieving a total power output from 1 mW to 10,000 W using an average power density from 0.1 W/cm 2  to 1 W/cm 2 . 
     
     
         13 . A method of treating arthritis and other rheumatic conditions, comprising:
 obtaining an arthritis and other rheumatic conditions reducing drug for treating arthritis and other rheumatic conditions based on:
 an acquired ultraweak photon emission image of a target area of a patient;
 wherein the target area comprises an area of interest and a portion surrounding the area of interest, 
 wherein acquired the ultraweak photon emission image comprises:
 enhancing formation of reactive oxygen species and/or reactive nitrogen species in the target area, 
  wherein enhancing formation of the reactive oxygen species and/or the reactive nitrogen species comprises applying low level light illumination to the target area from 1 second to 60 minutes, and 
 imaging the target area, 
  wherein imaging the target area comprises a total exposure time from 1 second to 60 minutes; 
 
 
 a measured amount of ultraweak photon emission in area of interest in the acquired image of the target area; and 
 a correlation of the measured amount of ultraweak photon emission in the area of interest of the target area to the arthritis and other rheumatic conditions reducing drug,
 wherein the arthritis and other rheumatic conditions reducing drug is selected from group consisting of nonsteroidal anti-inflammatory drugs, counterirritants, anti-inflammatory drugs, disease-modifying antirheumatic drugs, biologic response modifiers, steroidal drug including but not limited to corticosteroids, Janus Kinase (JAK) inhibitors, or any combination thereof; and 
 
   administering the arthritis and other rheumatic conditions reducing drug to treat the arthritis and other rheumatic conditions.   
     
     
         14 . The method of  claim 13 , wherein applying low level light illumination to the target area comprises achieving a total power output from 1 mW to 10,000 W using an average power density from 0.1 W/cm 2  to 1 W/cm 2 .